Lemborexant

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Lemborexant
   1. Pharmacist Assessment Report
   2. Lemborexant: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Lemborexant: Known uses and market status in Canada

Summary

The TxGNN model produced candidates for Lemborexant, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. This page lists the known-use groups for reference and the market status in Canada.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	0
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02507366	DAYVIGO		Valid
02507374	DAYVIGO		Valid

Safety Considerations

• Contraindications recorded in the knowledge graph (these are not label text and need verification against the Canadian product monograph): narcolepsy, narcolepsy-cataplexy syndrome, central nervous system disease, Balo concentric sclerosis, X-linked adrenoleukodystrophy.
• Drug Interactions: 100 interactions were identified. Examples rated Major: ranitidine, aprepitant, morphine (including liposomal morphine), cimetidine, clarithromycin and clotrimazole. Examples rated Moderate: pioglitazone, bupropion, dexamethasone, saxagliptin, diphenoxylate, dronabinol, nabilone, metoclopramide and others. Many of the major interactions involve CYP3A inhibitors or CNS depressants, which warrants dose and sedation review.

Please refer to the package insert for official warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---